Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Low BCL11A Expression in the Myeloma Microenvironment at Diagnosis Is Associated with Early Development of MDS Cytogenetic Abnormalities and Poor Overall Survival

Bounleut Phanavanh, Priyangi Malaviarachchi, Adam Rosenthal, Yogesh Jethava, MB, MRCP, MD FRCPath, Bart Barlogie, MD PhD, Jeffrey Sawyer, PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Sarah K. Johnson, PhD

Blood (2014) 124 (21): 2012.

https://doi.org/10.1182/blood.V124.21.2012.2012

Published: 2014

Journal Articles

Evidence of an Epigenetic Origin for High-Risk 1q21 Copy Number Aberrations in Multiple Myeloma

Jeffrey Sawyer, PhD, Erming Tian, PhD, Christoph Heuck, MD, Donald Johann, MD MS, Joshua Epstein, DSc, Charles Swanson, Janet Lukacs, Regina Lichti Binz, Gael Sammartino, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Bart Barlogie, MD, PhD

Blood (2014) 124 (21): 725.

https://doi.org/10.1182/blood.V124.21.725.725

Published: 2014

Journal Articles

Cytogenetic Features Of Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS) and Asymptomatic Multiple Myeloma (AMM)

Erming Tian, PhD, Sarah Waheed, MD, Jeffrey Sawyer, PhD, Qing Zhang, PhD, Christoph Heuck, MD, Madhav V. Dhodapkar, MD, Bart Barlogie, MD, PhD, Joshua Epstein, DSc

Blood (2013) 122 (21): 3108.

https://doi.org/10.1182/blood.V122.21.3108.3108

Published: 2013

Journal Articles

Role Of Cytogenetic Abnormalities At Baseline and During 5-Year Follow-Up In Multiple Myeloma Patients Treated On The Total Therapy 3 Protocol

Sarah Waheed, MD, Jeffrey Sawyer, PhD, Adam Rosenthal, Frits van Rhee, MD, PhD, Nathan M Petty, MS, Saad Z Usmani, MD, FACP, Clyde Bailey, Christoph Heuck, MD, Antje Hoering, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 3137.

https://doi.org/10.1182/blood.V122.21.3137.3137

Published: 2013

Journal Articles

Total Therapy (TT) Studies For Gene Expression Profiling (GEP)-Defined High-Risk Multiple Myeloma

Christoph Heuck, MD, Frits van Rhee, MD, PhD, Alan Mitchell, Adam Rosenthal, Sarah Waheed, MD, Nathan M Petty, MS, Clyde Bailey, Ryan Williams, Ryan van Laar, PhD, Susan B. Panozzo, BS, Jeffrey Sawyer, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 126.

https://doi.org/10.1182/blood.V122.21.126.126

Published: 2013

Journal Articles

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Blood (2013) 121 (23): 4753–4757.

https://doi.org/10.1182/blood-2012-11-466961

Published: 2013

Includes: Supplemental data

Journal Articles

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

Saad Z Usmani, MD FACP, Adam Rosenthal, Rachael Sexton, Antje Hoering, Zeba N Singh, MD, Sarah Waheed, MD, Al-Ola Abdallah, MD, Jameel Muzaffar, MD, Nathan M Petty, John Crowley, PhD, Jeffrey Sawyer, PhD, Joshua Epstein, DSc, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 324.

https://doi.org/10.1182/blood.V120.21.324.324

Published: 2012

Journal Articles

FISH and GEP Based Prediction of Chromosomal Translocation Identifies Myeloma Patients Who Do Not Benefit From Bortezomib

Erming Tian, Qing Zhang, Christoph Heuck, MD, Shweta S. Chavan, PhD, Jeffrey Sawyer, PhD, Saad Z Usmani, MD FACP, Joshua Epstein, DSc, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 1814.

https://doi.org/10.1182/blood.V120.21.1814.1814

Published: 2012

Journal Articles

Hyperhaploid Multiple Myeloma (MM): A Rare Karyotypic Subgroup Retaining Disomy 18 and 1q12∼23 Amplification

Jeffrey Sawyer, Erming Tian, Christoph Heuck, MD, Qing Zhang, Janet Lukacs, Regina Lichti Binz, Edward Thomas, Gael Sammartino, Charles Swanson, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Frits van Rhee, MD, PhD, Bart Barlogie, MD

Blood (2012) 120 (21): 3983.

https://doi.org/10.1182/blood.V120.21.3983.3983

Published: 2012

Journal Articles

Prediction of Cytogenetic Abnormalities in Multiple Myeloma Based on Gene Expression Profiles

Yiming Zhou, PhD, Qing Zhang, PhD, Christoph Heuck, MD, Owen Stephens, Erming Tian, PhD, Jeffrey Sawyer, PhD, Marie-Astrid Cartron-Mizeracki, MS, Bart Barlogie, MD, PhD, John D Shaughnessy, Jr., PhD

Blood (2011) 118 (21): 629.

https://doi.org/10.1182/blood.V118.21.629.629

Published: 2011

Journal Articles

Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC)

Jeffrey Sawyer, Erming Tian, PhD, John D. Shaughnessy, Jr., PhD, Janet Lukacs, Regina Lichti Binz, Edward Thomas, Gael Sammartino, Charles Swanson, Christoph Heuck, MD, Yazan Alsayed, MD, Elias J. Anaissie, MD, Bijay Nair, MD, Sarah Waheed, MD, Saad Usmani, MD, FACP, Frits van Rhee, MD, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 298.

https://doi.org/10.1182/blood.V118.21.298.298

Published: 2011

Journal Articles

Elevated Homologous Recombination Induces Karyotypic Changes and Predicts Poor Clinical Outcome In Multiple Myeloma

Jagannath Pal, Jeffrey Sawyer, Samir B. Amin, MBBS, Cheng Li, Puru Nanjappa, Saem Lee, B.A., Stephane Minvielle, Hervé Avet-Loiseau, Masood Shammas, Nikhil C. Munshi

Blood (2010) 116 (21): 1924.

https://doi.org/10.1182/blood.V116.21.1924.1924

Published: 2010

Journal Articles

Only Concomitant Presence of Cytogenetic Abnormalities in Randomly Sampled Bone Marrow and in MRI-Defined Focal Lesions Imparts Poor Prognosis and Is Associated with Gene Expression Profiling (GEP)-Based High-Risk Myeloma.

Bijay Nair, PhD, Yiming Zhou, PhD, Bart Barlogie, MD, PhD, Jeffrey Sawyer, PhD, Jackie Szymonifka, John Crowley, PhD, John D. Shaughnessy, Jr., PhD

Blood (2008) 112 (11): 1691.

https://doi.org/10.1182/blood.V112.11.1691.1691

Published: 2008

Journal Articles

A Novel Mechanism for Intrachromosomal Gene Amplification in Multiple Myeloma: 1q12 Pericentromeric Heterochromatin Mediates Breakage- Fusion-Bridge Cycles of the 1q12~23 Amplicon

Jeffrey Sawyer, Erming Tian, Edward Thomas, Mark Koller, Collin Stangeby, Gael Sammartino, Linda Goosen, Charles Swanson, Regina Lichti Binz, Bart Barlogie, John Shaughnessy

Blood (2008) 112 (11): 493.

https://doi.org/10.1182/blood.V112.11.493.493

Published: 2008

Journal Articles

Integration of DNA Copy Number and Gene Expression Alterations Reveal Novel Insights into the Molecular Pathogenesis and Prognosis of Multiple Myeloma

Yiming Zhou, PhD, Bart Barlogie, MD, PhD, Damir Herman, PhD, Owen Stephens, PhD, Erming Tian, PhD, David Williams, PhD, Marie-astrid Cartron, PhD, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, PhD, Yazan Alsayed, MD, PhD, Elias Anaissie, MD, PhD, Jeffrey Sawyer, Ph.D., John D. Shaughnessy, Jr., PhD

Blood (2008) 112 (11): 250.

https://doi.org/10.1182/blood.V112.11.250.250

Published: 2008

Journal Articles

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989

Bart Barlogie, Guido Tricot, Jeff Haessler, Frits van Rhee, Michele Cottler-Fox, Elias Anaissie, James Waldron, Mauricio Pineda-Roman, Raymond Thertulien, Maurizio Zangari, Klaus Hollmig, Abid Mohiuddin, Yazan Alsayed, Antje Hoering, John Crowley, Jeffrey Sawyer

Blood (2008) 111 (1): 94–100.

https://doi.org/10.1182/blood-2007-06-097444

Published: 2008

Journal Articles

Metaphase Cytogenetics Adds to Gene Expression Profiling in the Identification of High Risk Multiple Myeloma.

Guido Tricot, MD, PhD, Fenghuang Zhan, MD, PhD, Bart Barlogie, MD, PhD, Yongsheng Huang, PhD, Jeffrey Sawyer, PhD, John Shaughnessy, PhD

Blood (2006) 108 (11): 114.

https://doi.org/10.1182/blood.V108.11.114.114

Published: 2006

Journal Articles

An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups.

John D. Shaughnessy, Jr., Jeffrey Haessler, Jerry Zeldis, Yongsheng Huang, Fenghuang Zhan, Jeffrey Sawyer, Elias Anaissie, Frits van Rhee, Guido Tricot, Joshua Epstein, Maurizio Zangari, Mauricio Pineda-Roman, Klaus Hollmig, John Crowley, Bart Barlogie

Blood (2006) 108 (11): 3389.

https://doi.org/10.1182/blood.V108.11.3389.3389

Published: 2006

Journal Articles

Testing Standard and Genetic Markers in 220 Patients with Multiple Myeloma (MM) with Complete Data Sets: Superiority of Molecular Genetics.

John D. Shaughnessy, Jr., Jeffrey Haessler, Ichiro Hanamura, Yongsheng Huang, James P. Stewart, Fenghuang Zhan, Jeffrey Sawyer, Elias Anaissie, Frits van Rhee, Guido Tricot, Joshua Epstein, Maurizio Zangari, Mauricio Pineda-Roman, Klaus Hollmig, John Crowley, Bart Barlogie

Blood (2006) 108 (11): 3391.

https://doi.org/10.1182/blood.V108.11.3391.3391

Published: 2006

Journal Articles

Focal Lesion (FL) Identification by MRI and Metastatic Bone Survey (MBS) in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2 (TT2).

Ronald Walker, Jeffrey Haessler, Guido Tricot, John D. Shaughnessy, Jr., Joshua Epstein, Jeffrey Sawyer, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Mauricio Pineda-Roman, Klaus Hollmig, John Crowley, Bart Barlogie

Blood (2006) 108 (11): 3496.

https://doi.org/10.1182/blood.V108.11.3496.3496

Published: 2006

NARROW

Low BCL11A Expression in the Myeloma Microenvironment at Diagnosis Is Associated with Early Development of MDS Cytogenetic Abnormalities and Poor Overall Survival

Evidence of an Epigenetic Origin for High-Risk 1q21 Copy Number Aberrations in Multiple Myeloma

Cytogenetic Features Of Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS) and Asymptomatic Multiple Myeloma (AMM)

Role Of Cytogenetic Abnormalities At Baseline and During 5-Year Follow-Up In Multiple Myeloma Patients Treated On The Total Therapy 3 Protocol

Total Therapy (TT) Studies For Gene Expression Profiling (GEP)-Defined High-Risk Multiple Myeloma

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

FISH and GEP Based Prediction of Chromosomal Translocation Identifies Myeloma Patients Who Do Not Benefit From Bortezomib

Hyperhaploid Multiple Myeloma (MM): A Rare Karyotypic Subgroup Retaining Disomy 18 and 1q12∼23 Amplification

Prediction of Cytogenetic Abnormalities in Multiple Myeloma Based on Gene Expression Profiles

Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC)

Elevated Homologous Recombination Induces Karyotypic Changes and Predicts Poor Clinical Outcome In Multiple Myeloma

Only Concomitant Presence of Cytogenetic Abnormalities in Randomly Sampled Bone Marrow and in MRI-Defined Focal Lesions Imparts Poor Prognosis and Is Associated with Gene Expression Profiling (GEP)-Based High-Risk Myeloma.

A Novel Mechanism for Intrachromosomal Gene Amplification in Multiple Myeloma: 1q12 Pericentromeric Heterochromatin Mediates Breakage- Fusion-Bridge Cycles of the 1q12~23 Amplicon

Integration of DNA Copy Number and Gene Expression Alterations Reveal Novel Insights into the Molecular Pathogenesis and Prognosis of Multiple Myeloma

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989

Metaphase Cytogenetics Adds to Gene Expression Profiling in the Identification of High Risk Multiple Myeloma.

An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups.

Testing Standard and Genetic Markers in 220 Patients with Multiple Myeloma (MM) with Complete Data Sets: Superiority of Molecular Genetics.

Focal Lesion (FL) Identification by MRI and Metastatic Bone Survey (MBS) in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2 (TT2).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only